Bristol-Myers: increases FY targets
(CercleFinance.com) - After unveiling better-than-expected quarterly results, Bristol-Myers Squibb says that it is now looking for adjusted EPS of between 4.
20 dollars and 4.30 dollars in 2019, up from a previous target range of 4.10 dollars to 4.20 dollars.
The pharmaceutical company posted Q2 2019 adjusted EPS growth of 17% at 1.18 dollar, which is twelve cents above the consensus.
Its revenues rose by 10% to nearly 6.3 billion dollars over the period (+13% excluding currency effects), mainly supported by its flagship products Opdivo (+24%) and Eliquis
(+12%).
Copyright (c) 2019 CercleFinance.com. All rights reserved.
20 dollars and 4.30 dollars in 2019, up from a previous target range of 4.10 dollars to 4.20 dollars.
The pharmaceutical company posted Q2 2019 adjusted EPS growth of 17% at 1.18 dollar, which is twelve cents above the consensus.
Its revenues rose by 10% to nearly 6.3 billion dollars over the period (+13% excluding currency effects), mainly supported by its flagship products Opdivo (+24%) and Eliquis
(+12%).
Copyright (c) 2019 CercleFinance.com. All rights reserved.